BioCentury
ARTICLE | Company News

SyStemix, Novartis deal

April 15, 2013 7:00 AM UTC

Novartis will acquire the 27 percent of STMX it does not already own for $19.50 per share (details, see BioCentury Extra, Jan. 14). The bid follows Novartis' October bid of $17, which was rejected b...